Celcuity (NASDAQ:CELC - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Celcuity Stock Up 0.8 %
CELC traded up $0.12 during trading on Friday, hitting $15.85. The company had a trading volume of 870,864 shares, compared to its average volume of 276,616. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $586.93 million, a PE ratio of -5.74 and a beta of 0.76. Celcuity has a one year low of $10.26 and a one year high of $22.19. The firm's 50-day moving average price is $15.27 and its 200 day moving average price is $16.12.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Lifesci Capital began coverage on Celcuity in a report on Monday, August 26th. They set an "outperform" rating and a $27.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners began coverage on shares of Celcuity in a report on Monday, July 22nd. They set an "outperform" rating and a $29.00 price target for the company. Finally, Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Celcuity currently has an average rating of "Buy" and an average price target of $29.17.
Check Out Our Latest Stock Report on Celcuity
Celcuity Company Profile
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
